STOCK TITAN
  1. Home
  2. News
  3. CDXC

ChromaDex Corporation - CDXC STOCK NEWS

Welcome to our dedicated page for ChromaDex Corporation news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on ChromaDex Corporation stock.

ChromaDex Corporation (NASDAQ: CDXC) is a pioneering global nutraceutical company dedicated to enhancing healthy aging through scientific advancements. The company's mission revolves around improving the way people age by focusing on the potential of nicotinamide adenine dinucleotide (NAD+), a critical coenzyme in metabolic processes that declines with age.

ChromaDex's team of scientists partners with renowned universities and research institutions worldwide to explore and develop innovative, science-based ingredients. Their flagship product, Tru Niagen®, is a supplement that features Niagen® (nicotinamide riboside), an NAD+ precursor aimed at promoting better aging. Alongside Tru Niagen®, ChromaDex's product portfolio includes PteroPure® (pterostilbene), PureEnergy® (a caffeine-pterostilbene co-crystal), and Anthorigin™ (anthocyanins).

The company operates through three primary segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The majority of ChromaDex's revenue is generated from its Consumer Products segment, driven by the popularity and efficacy of Tru Niagen®.

ChromaDex's commitment to scientific research is evident in its numerous collaborations with academic institutions. These partnerships aim to uncover the full potential of NAD+ and other beneficial compounds to develop products that support health and longevity.

The company's stock is publicly traded on NASDAQ under the symbol CDXC. For more information on ChromaDex, visit their website at www.chromadex.com, follow them on Twitter @chromadex, or like their Facebook page here.

Recent Achievements and Current Projects:

  • Continued research and development into NAD+ and its related compounds.
  • Expansion of Tru Niagen® into new markets globally.
  • Ongoing partnerships with leading universities and research institutions.
  • Innovative new product launches aimed at further promoting healthy aging.
News

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023

Rhea-AI Summary
ChromaDex Corporation (NASDAQ: CDXC) to Participate in Renmark Financial Communications Inc.’s Virtual Non-Deal Roadshow Series on November 14, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.25%
Tags
conferences
-
News

ChromaDex Corporation Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
ChromaDex Corp. (NASDAQ: CDXC) announced third-quarter 2023 financial results, including $19.5 million in net sales, a 61.4% gross margin, and a $1.0 million net loss. Key highlights are Tru Niagen® sales growth and a positive Adjusted EBITDA of $0.5 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.25%
Tags
earnings
-
News

ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide

Rhea-AI Summary
ChromaDex Corp. launches Tru Niagen Pro 1,000mg, a clinical strength supplement proven to boost NAD+ levels by up to 150% in as little as three weeks. The product features 1,000mg of Niagen, a superior quality NAD+ precursor. It is recommended by physicians and used by pro-athletes. Tru Niagen Pro 1,000mg is Certified for Sport® by NSF International.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
none
News

ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) will hold a conference call on November 8, 2023, at 4:30 p.m. ET to discuss its financial results for the third quarter of 2023. The results will be reported in a press release after the close of regular stock market trading hours on the same day. The conference call will be broadcast live and available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News

ChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line

Rhea-AI Summary
ChromaDex and Zesty Paws launch Healthy Aging NAD+ Precursor supplement for dogs
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
none
-
News

A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients

Rhea-AI Summary
ChromaDex Corp shares results from a clinical study showing that supplementation with nicotinamide riboside (NR) reduces inflammation in healthy subjects and psoriasis patients. NR is proven to increase NAD+ levels safely and effectively. This research supports the anti-inflammatory effects of NR in both healthy individuals and those with inflammation-related disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News

Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN

Rhea-AI Summary
ChromaDex Corp. shares findings from a preclinical study on NMN and NR, indicating that NR is a more efficient NAD+ precursor than NMN. NMN cannot cross the cell membrane directly and must first be converted to NR. NR was 25% more effective in raising whole blood NAD+ levels compared to NMN in a clinical study. NMN's phosphate group prevents it from entering the cell directly, while NR can be directly imported into human cells. The U.S. FDA's decision to disallow NMN as a dietary supplement does not affect NR.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
clinical trial
-
News

ChromaDex Corporation Reports Second Quarter 2023 Financial Results

Rhea-AI Summary
ChromaDex Corp. (NASDAQ:CDXC) announced strong Q2 2023 results with total net sales of $20.3 million, a gross margin of 60.8%, and a net loss of $2.2 million. Key highlights include a positive Adjusted EBITDA of $0.2 million, significant revenue growth, and positive operating cash flows. The company's 2023 revenue outlook was raised by 2.5% to at least 15% growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
earnings
-
News

ChromaDex Launches Tru Niagen® with iHerb, the World’s Number One Online Destination for Health and Wellness

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.47%
Tags
none
News

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
conferences

FAQ

What is the current stock price of ChromaDex Corporation (CDXC)?

The current stock price of ChromaDex Corporation (CDXC) is $7.44 as of November 22, 2024.

What is the market cap of ChromaDex Corporation (CDXC)?

The market cap of ChromaDex Corporation (CDXC) is approximately 559.1M.

What is ChromaDex Corporation's main focus?

ChromaDex focuses on improving healthy aging through scientific research and the development of NAD+ related supplements.

What is Tru Niagen®?

Tru Niagen® is a dietary supplement formulated with Niagen® (nicotinamide riboside), which helps boost NAD+ levels to support healthy aging.

How does ChromaDex generate most of its revenue?

The majority of ChromaDex's revenue comes from its Consumer Products segment, particularly the sales of Tru Niagen®.

On which stock exchange is ChromaDex traded?

ChromaDex is publicly traded on NASDAQ under the symbol CDXC.

What are some of ChromaDex's other products?

In addition to Tru Niagen®, ChromaDex offers PteroPure® (pterostilbene), PureEnergy® (caffeine-pterostilbene co-crystal), and Anthorigin™ (anthocyanins).

Who are ChromaDex's research partners?

ChromaDex collaborates with leading universities and research institutions worldwide to advance their scientific research.

What is NAD+?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme essential for metabolic processes, which declines with age.

Where can I find more information about ChromaDex?

More information about ChromaDex can be found on their website at www.chromadex.com.

Does ChromaDex offer services apart from consumer products?

Yes, ChromaDex also operates in the Ingredients segment and the Analytical Reference Standards and Services segment.

How is ChromaDex contributing to healthy aging research?

ChromaDex contributes to healthy aging research through its extensive studies on NAD+ and partnerships with global research institutions.

Stock CDXC logo
ChromaDex Corporation

Nasdaq:CDXC

CDXC Rankings

#3033 Ranked by Market Cap
N/A Ranked by Dividends

CDXC Stock Data

559.14M
49.35M
35.39%
23.87%
3.41%
Packaged Foods
Medicinal Chemicals & Botanical Products
Link
United States of America
LOS ANGELES